Clinical Trial Update: GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GEMOX (gemcitabine and oxaliplatin) in docetaxel-refractory castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)

Snippet

Sponsor: Asan Medical Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED